PFESeagen Inc.Finished
A Study of SEA-CD40 Given With Other Drugs in Cancers
Melanoma · Carcinoma, Non-Small- Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 77 (final count)
- Started
- Oct 6, 2021
- Main results expected
- Jan 3, 2024
- Fully finished
- Nov 25, 2024
- Results posted
- Jan 22, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (cORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Per Investigator Assessment
Measured over: From start of study treatment until CR or PR (maximum up to 15.2 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04993677 · record last updated 2025-05-11 · checked 2026-11-09 15:36 UTC